The companies have agreed not to disclose additional details and respect customer confidentiality
CordenPharma has signed a multi-year agreement commencing in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility.
The manufacturing agreement will potentially cover the value of around USD $1 billion, depending on actual production over the term of the agreement, and will support the launch of an innovative peptide. The companies have agreed not to disclose additional details and respect customer confidentiality.
We plan to further expand both our large and medium-scale peptide manufacturing capacity at our Colorado and Frankfurt sites
Dr Michael Quirmbach, CEO & President of CordenPharma, commented: “We are very excited about the trust our customer has placed in CordenPharma, and are pleased to continue supporting the commercial manufacturing of this innovative peptide at our CordenPharma Colorado (US) site, which is perfectly equipped for producing these types of complex molecules.”
In parallel, CordenPharma is pursuing a large investment program across its global facility network to expand capacities and technologies in key areas such as peptides, lipids, and injectables, with an overall planned investment of roughly €200M in 2023.
Dr Quirmbach continued: “As part of our commitment, we plan to further expand both our large and medium-scale peptide manufacturing capacity at our Colorado and Frankfurt sites, making CordenPharma the leading peptide manufacturing CDMO with full drug product integration, possible via our aseptic fill and finish capabilities in CordenPharma Caponago.”